Robert Dunne - CEO Glycoselect

GlycoSeLect announces opening of new laboratory facility and start of Series A fund raising round

Dublin, Ireland – 5th March 2020 – GlycoSelect Ltd, the Irish Biotechnology company, which specialises in the development of separation technology to enhance biopharmaceutical product analysis and manufacturing, today announced a Series A Funding round together with further expansion of additional laboratory space at the Dublin City University Campus in Dublin in order to meet customer demand.

The launch of its Series A funding round of $1m comes on the back of securing seed capital from Enterprise Ireland and KBI Biopharma Inc of approx. $600k during 2017.

The company recently entered into a joint licencing and development agreement with U.S. based JSR Life Sciences for the development of glycan-affinity ligand and capture resin for manufacturing applications, as well as continuing to work with a global biopharmaceutical company on research into Cell and Gene Therapy manufacturing applications using GlycoSeLect’s RPL technology.

According to Robert Dunne, CEO at GlycoSelect Ltd, this funding round will allow us to further expand our technology applications and supporting business development efforts, particularly in Europe and the U.S., to provide world-class glycoprotein separation solutions for biopharmaceutical product development and manufacturing.

Richard Stokes, Director of Commercialisation at DCU commented “We are delighted to see Glycoselect expanding, and we continue to actively support the commercialisation of intellectual property originally created at DCU and further developed by Glycoselect for the biopharmaceutical sector”

 

Contact

Robert Dunne

CEO

GlycoSelect Ltd

Hamilton Building

Dublin City University

Glasnevin

Dublin 9

Ireland

Tel; + 353 87 7902652

Email: Robert.dunne@glycoselect.com

About GlycoSelect Ltd

GlycoSeLect Ltd develops innovative technologies for the analysis, characterisation and purification of biopharmaceuticals. These next-generation products are highly specific for glycan structures improving product development and improving the cost-efficiency of their manufacturing. GlycoSeLect specialises in the development of proteins based on recombinant prokaryotic lectins RPLs. Our RPL products advance efficient detection, analysis and selective isolation of glycosylated pharmaceutical products. GlycoSeLect’s family of RPLs products are associated with market-leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness in process development.

More Stories

Menu